Ruitao Lin
Department of Biostatistics, Division of Basic Sciences
About Ruitao Lin
Dr. Ruitao Lin's personal website can be found at https://ruitaolin.weebly.com.
Read More
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Biostatistics, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Regular Member, MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX
Dual/Joint/Adjunct Appointment
Adjunct Assistant Professor, Rice University, Houston, TX
Education & Training
Degree-Granting Education
| 2016 | The University of Hong Kong, Hong Kong, HKG, PHD, Biostatistics |
| 2012 | The Hong Kong University of Science and Technology, Hong Kong, HKG, MS, Financial Mathematics |
Postgraduate Training
| 2017-2019 | Research Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2016-2017 | Research Fellowship, University of Washington, Seattle, WA |
Selected Publications
Peer-Reviewed Articles
- Zheng S, Lin R, Guo J, and Yin G. Testing homogeneity of high-dimensional covariance matrices. Statistica Sinica 30(1), 2020.
- Lam CK, Lin R, and Yin G. Non‐parametric overdose control for dose finding in drug combination trials. Journal of the Royal Statistical Society: Series C (Applied Statistics) 68(4):1111-1130, 2019.
- Zhong YJ, Wen YF, Wong HM, Yin G, Lin R, Yang SY. Trends and Patterns of Disparities in Burden of Lung Cancer in the United States, 1974-2015. Front Oncol 9:404, 2019. e-Pub 2019. PMID: 31214489.
- Lin R, Yuan Y. On the relative efficiency of model-assisted designs: a conditional approach. J Biopharm Stat 29(4):648-662, 2019. e-Pub 2019. PMID: 31258039.
- Lin R. Bayesian optimal interval design with multiple toxicity constraints. Biometrics 74(4):1320-1330, 2018. e-Pub 2018. PMID: 29870069.
- Lin R, Yin G. Uniformly most powerful Bayesian interval design for phase I dose-finding trials. Pharm Stat 17(6):710-724, 2018. e-Pub 2018. PMID: 30066466.
- Yuan Y, Lin R, Li D, Nie L, Warren KE. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clin Cancer Res 24(20):4921-4930, 2018. e-Pub 2018. PMID: 29769209.
- Lin R, Yin G. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials. Stat Med 36(26):4106-4120, 2017. e-Pub 2017. PMID: 28786138.
- Lin R, Yin G. Bayesian optimal interval design for dose finding in drug-combination trials. Stat Methods Med Res 26(5):2155-2167, 2017. e-Pub 2015. PMID: 26178591.
- Lin R, Yin G. Nonparametric overdose control with late-onset toxicity in phase I clinical trials. Biostatistics 18(1):180-194, 2017. e-Pub 2016. PMID: 27549121.
- Lin R, Liu Z, Zheng S, Yin G. Power computation for hypothesis testing with high-dimensional covariance matrices. Computational Statistics & Data Analysis 104:10-23, 2016.
- Lin R, Yin G. Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials 10:2349-2376, 2016.
- Lin R, Yin G. Bayes factor and posterior probability: Complementary statistical evidence to p-value. Contemp Clin Trials 44:33-35, 2015. e-Pub 2015. PMID: 26212520.
- Wen YF, Wong HM, Lin R, Yin G, McGrath C. Inter-Ethnic/Racial Facial Variations: A Systematic Review and Bayesian Meta-Analysis of Photogrammetric Studies. PLoS One 10(8):e0134525, 2015. e-Pub 2015. PMID: 26247212.
- Yin G, Lin R. Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, and S. Zohar. Stat Med 34(1):13-7, 2015. PMID: 25492615.
- Park Y, Lin R. Discussion on "Predictively consistent prior effective sample sizes," by Beat Neuenschwander, Sebastian Weber, Heinz Schmidli, and Anthony O'Hagan. Biometrics. e-Pub 2020. PMID: 32251522.
- Pan H, Lin R, Zhou Y, Yuan Y. Keyboard design for phase I drug-combination trials. Contemp Clin Trials:105972. e-Pub 2020. PMID: 32151751.
- Lin R, Thall PF, Yuan Y. BAGS: A Bayesian adaptive group sequential trial design for subgroup-specific survival comparisons. Journal of American Statistical Association.
- Park Y, Lin R. Dicussion of “Predictively consistent prior effective sample sizes” by Neuenschwander et al. Biometrics.
- Lin R, Thall PF, Yuan Y. An adaptive trial design to optimize dose-schedule regimes with delayed outcomes. Biometrics. e-Pub 2019. PMID: 31273750.
- Lin R, Yuan Y. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity. Biostatistics. e-Pub 2019. PMID: 30984972.
- Lin R, Coleman RL, Yuan Y. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. J Natl Cancer Inst. e-Pub 2019. PMID: 30924863.
Book Chapters
- Lin R, Lee JJ. Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials. In: Computational and Methodological Statistics and Biostatistics. Springer, 2020.
- Yuan Y, Lin R. Novel Designs for Early Phase Drug Combination Trials. In: Bayesian Applications in Pharmaceutical Development. Chapman and Hall/CRC, 2019.
- Lin R, Yin G. Random Walk and Parallel Crossing Bayesian Optimal Interval Design for Dose Finding with Combined Drugs. In: Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer Singapore, 2017.
- Lin R, Yin G. Robust Optimal Interval Design for High-Dimensional Dose Finding in Multi-agent Combination Trials. In: Advanced Statistical Methods in Data Science. Springer, Singapore, 2016.
- Yin G, Lin R. Continual reassessment methods. In: Modern Approaches to Clinical Trials Using SAS: Classical, Adaptive, and Bayesian Methods. SAS Institute, 2015.
- Lin R, Yin G. Adaptive randomization. In: Modern Approaches to Clinical Trials Using SAS: Classical, Adaptive, and Bayesian Methods. SAS Institute, 2015.
- Lin R, Yin G. Sample size re-estimation in adaptively randomized clinical trials with missing data. In: Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects. Chapman and Hall/CRC, 2015.